We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0ABW market cap is 0. The company's latest EPS is SEK and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 82.56M | 40.66M | 38.5M | 22.6M | 57.6M |
| Operating Income | -66.61M | -178.15M | -105.6M | -197M | -320.2M |
| Net Income | -61.42M | -179.12M | -104.5M | -193.8M | -326.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 270.07M | 893.97M | 569.3M | 561.1M | 760.2M |
| Total Liabilities | 25.2M | 264.34M | 42.3M | 54.9M | 214.6M |
| Total Equity | 244.88M | 629.63M | 527M | 506.2M | 545.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -62.64M | -134.64M | -130.1M | -173.5M | -278.4M |
| Investing | N/A | -59.54M | -6M | -1.7M | N/A |
| Financing | 86.72M | 228.41M | -8.9M | 155.7M | 458.9M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 292.57M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Egetis Therapeutics Ab (publ) |
| Address |
grev turegatan 11 c stockholm 114 46 |
| Website | https://www.egetis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
